Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 2/20 | 0.32 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848270 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4RARARARGRXRA | |
| SCHEMBL5849355 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA4RARARARGRXRA | |
| SCHEMBL5847850 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL5847841 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL5847985 | 0.73 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL5847977 | 0.73 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL5848281 | 0.72 | CHRNB2 (0.34) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL5848280 | 0.72 | CHRNB2 (0.34) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL5848286 | 0.72 | CHRNB2 (0.34) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL5848254 | 0.71 | CHRNB2 (0.48) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022706-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-6624167-B1 | Compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-1305316-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | Targacept, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002012245-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | TARGACEPT, INC. (US) | 2002-02-14 | — | — | WO | disclosed |